ArticlePharmaceutics2020
Development of Metronidazole Loaded Chitosan Nanoparticles Using QbD Approach-A Novel and Potential Antibacterial Formulation.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 77 citations in OpenAlex.
- QbD Optimized Nanoemulsion Based Topical Formulation of Jatyadi Taila: Unveiling its In Vitro and In Vivo Efficacy for Enhanced Wound Healing.Pharmaceutical research · 2025Article
- Antibacterial Activity of Fusidic Acid-Loaded Electrospun Polylactide Fiber Fleeces Against Periodontopathogenic Species.Pharmaceutics · 2025Article
- Cost-Effective Nanosensor Solutions for Ultra-Sensitive Detection of Metronidazole.Analytical science advances · 2025Review
- Metronidazole-Loaded Chitosan Nanoparticles with Antimicrobial Activity AgainstPharmaceutics · 2025Article
- Quality-by-design-engineered mitochondrial targeted nanoparticles for glioblastoma therapy.RSC advances · 2024Article
- Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone.International journal of nanomedicine · 2024Review
- Telmisartan-Loaded Lactosylated Chitosan Nanoparticles as a Liver Specific Delivery System: Synthesis, Optimization and Targeting Efficiency.AAPS PharmSciTech · 2023Article
- Qbd-Based Approach to Optimize Niosomal Gel of Levosulpiride for Transdermal Drug Delivery.Gels (Basel, Switzerland) · 2023Article
- Intranasal Administration of Dolutegravir-Loaded Nanoemulsion-Based In Situ Gel for Enhanced Bioavailability and Direct Brain Targeting.Gels (Basel, Switzerland) · 2023Article
- Enhancement of antifungal activity and transdermal delivery of 5-flucytosine via tailored spanlastic nanovesicles: statistical optimization,Frontiers in pharmacology · 2023Article
- Compression-coated pulsatile chronomodulated therapeutic system: QbD assisted optimization.Drug delivery · 2022Article
- Formulation, Characterization, Anti-Inflammatory and Cytotoxicity Study of Sesamol-Laden Nanosponges.Nanomaterials (Basel, Switzerland) · 2022Article
- Article
- Formulation-by-Design of Efinaconazole Spanlastic Nanovesicles for Transungual Delivery Using Statistical Risk Management and Multivariate Analytical Techniques.Pharmaceutics · 2022Article
- Metronidazole Delivery Nanosystem Able To Reduce the Pathogenicity of Bacteria in Colorectal Infection.Biomacromolecules · 2022Article
- Adenosine Conjugated Docetaxel Nanoparticles-Proof of Concept Studies for Non-Small Cell Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update.Pharmaceutics · 2022Review
- Itraconazole loaded nano-structured lipid carrier for topical ocular delivery: Optimization and evaluation.Saudi journal of biological sciences · 2022Article
- Encapsulation of Metronidazole in Biocompatible Macrocycles and Structural Characterization of Its Nano Spray-Dried Nanostructured Composite.Molecules (Basel, Switzerland) · 2021Article
- Optimized Rivastigmine Nanoparticles Coated with Eudragit for Intranasal Application to Brain Delivery: Evaluation and Nasal Ciliotoxicity Studies.Materials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
The aim of this study was to design, optimize, and develop metronidazole (Met) loaded nanoparticles (MetNp) by employing quality-based design (QbD) as well as a risk assessment methodology. A fractional factorial design was used by selecting five independent variables viz., chitosan concentration, tripolyphosphate concentration, and acetic acid concentration as material attributes, stirring speed, and stirring time as process parameters, whereby their influence on two dependent variables such as particle size (PS) and %entrapment efficiency (%EE) was studied. MetNp were synthesized by employing an ionic-gelation technique and optimized formula obtained from the QbD design study. PS and %EE studies revealed the formation of MetNp with 558.06 ± 2.52 nm and 59.07 ± 2.15%, respectively. Furthermore, a Met release study in various simulated gastro-intestinal media suggested pH-triggered (pH > 7.0) and sustained release profile of Met from Eudragit S100 enteric-coated MetNp capsule (MetNp cap). Moreover, the stability investigation of formulations confirmed good stability with respect to their PS and residual drug content (RDC) at different temperature conditions. In conclusion, the QbD method was effectively utilized in the development of MetNp and enteric-coated MetNp cap depicting their potential to release Met through MetNp cap only in the colon region and can be utilized for the treatment of amoebiasis in the colon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.